Publication
Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center
| dc.contributor.author | Bezerra de-Mello, Ramon Andrade | |
| dc.contributor.author | Pinho-Vaz, Carlos | |
| dc.contributor.author | Branca, Rosa | |
| dc.contributor.author | Campilho, Fernando | |
| dc.contributor.author | Rosales, Maria | |
| dc.contributor.author | Roncon, Susana | |
| dc.contributor.author | Campos-Junior, Antonio | |
| dc.date.accessioned | 2017-04-07T15:55:54Z | |
| dc.date.available | 2017-04-07T15:55:54Z | |
| dc.date.issued | 2016-10 | |
| dc.description.abstract | Introduction: Allogeneic hematopoietic stem cell transplantation (ASCT) represents a potentially curative approach for patients with relapsed or refractory acute myeloid leukemia (AML). We report the outcome of relapsed/refractory AML patients treated with ASCT.Method: A retrospective cohort from 1994 to 2013 that included 61 patients with diagnosis of relapsed/refractory AML. Outcomes of interest were transplant-related mortality (TRM), incidence of acute and chronic graft-versus-host disease (GVHD), relapse incidence, progression-free survival (PFS) and overall survival (OS). Statistical significance was set at p<0.05.Results: The median age was 61 years (range 1 to 65). The cumulative incidence of 90 days, 1 year, and 3 years TRM were 60%, 26.7%, and 13.3%, respectively (p< 0.001). The incidence of relapse was 21.7% at 1 year, 13% at 3 years, and 8.7% at 5 years. Median OS was estimated to be 8 months (95CI 3.266-12.734) and median PFS, 3 months (95CI 1.835-4.165).Conclusion: In our cohort, TRM in first years after ASCT remains considerable, but ASCT in this setting seems to be a good choice for AML patients with active disease. However, novel approaches are needed to reduce TRM and relapse in this set of patients. | |
| dc.identifier.doi | 10.1590/1806-9282.62.07.641 | |
| dc.identifier.issn | 0104-4230 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/9254 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.relation.isbasedon | WOS:000390438500008 | |
| dc.subject | Acute myeloid leukemia | |
| dc.subject | Heterologous transplantation | |
| dc.subject | Bone marrow neoplasms | |
| dc.title | Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center | |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 646 | |
| oaire.citation.issue | 7 | |
| oaire.citation.startPage | 641 | |
| oaire.citation.title | Revista da Associação Médica Brasileira | |
| oaire.citation.volume | 62 | |
| rcaap.rights | openAccess | |
| rcaap.type | article |
Files
Original bundle
1 - 1 of 1